<DOC>
	<DOCNO>NCT00717678</DOCNO>
	<brief_summary>The purpose study compare efficacy safety Prograf extend release ( XL ) plus MMF Prograf plus MMF de novo kidney transplant recipient .</brief_summary>
	<brief_title>A Randomized Study Assess Safety Efficacy Prograf vs Prograf-XL de Novo Kidney Transplant Recipients</brief_title>
	<detailed_description />
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<criteria>Patient fully inform signed IRB approve informed consent form willing able follow study procedure Patient recipient primary retransplanted cadaveric nonHLAidentical living kidney transplant Patient must receive first oral dose randomize study drug within 48 hour transplant procedure Female patient child bear potential must negative urine serum pregnancy test within 7 day prior enrollment upon hospitalization Patient previously receive receive organ transplant kidney Patient receive kidney transplant nonheart beat donor Patient receive ABO incompatible donor kidney Recipient donor know seropositive human immunodeficiency virus ( HIV ) Patient current malignancy history malignancy ( within past 5 year ) , except nonmetastatic basal squamous cell carcinoma skin treat successfully Patient significant liver disease , define past 28 day continuously elevate AST ( SGOT ) and/or ALT ( SGPT ) level great 3 time upper value normal range investigational site Patient uncontrolled concomitant infection unstable medical condition could interfere study objective Patient currently take take investigational drug 30 day prior transplant Patient receive everolimus enteric coat mycophenolic acid time study Patient know hypersensitivity tacrolimus , mycophenolate mofetil corticosteroid Patient pregnant lactate Patient unlikely comply visit schedule protocol Patient form substance abuse , psychiatric disorder condition , opinion investigator , may invalidate communication investigator</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Immunosuppressant</keyword>
	<keyword>Combination drug therapy</keyword>
	<keyword>Graft loss</keyword>
	<keyword>Randomized control trial</keyword>
	<keyword>Open level method</keyword>
</DOC>